July 18, 2024
Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 | Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for COVID-19 |
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity |
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19 |
Comparative Effectiveness of Combination Therapy with Nirmatrelvir–ritonavir and Remdesivir versus Monotherapy with Remdesivir | Postacute Sequelae of SARS-CoV-2 Infection |
The Efficacy of Antivirals, Corticosteroids, and mAbs as Acute COVID Treatments